SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

GPCR

Structure Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 5h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Watch for aleniglipron body composition, T2DM and SWITCH data expected in Q4 2026, which could de-risk the Phase 3 program. ACCG-2671 MAD data in 1H 2027 is the next major pipeline catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

GPCR drug pipeline →

ACCG-2671

● Neutral Named in this press release
Impact
Phase
Phase 1/2a
Time to market
Given that ACCG-2671 is still in Phase 1/2a, potential approval is likely many years away (probably 2029-2031 at the earliest), assuming successful clinical development.
Next catalyst
None dated

What to watchACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$21.73
T+0 close · Nov 9, 2026 · via day close
Latest settled
−3.59%
T+1 · $20.95
Vs SPY
−4.91%
α at T+1
Next horizon
T+5
in 9h
  1. T+0 · Nov 10 $21.73entry
  2. T+1 · 6d ago −3.59%α −4.91% · $20.95
  3. T+4 · todayOpen
  4. T+5 · in 9h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3 2025, driven by increased R&D spending as the Phase 3 ACCOMPLISH program for aleniglipron initiates. Cash burn was $60M sequentially, leaving $1.2B in cash expected to fund operations through 2028. Key catalysts include aleniglipron supplementary data in Q4 2026 and ACCG-2671 MAD data in 1H 2027.

Key Facts

  • Net loss of $144.8M in Q3 2026 vs $65.7M in Q3 2025
  • Cash, cash equivalents and short-term investments of $1.2B as of Sep 30, 2026, down from $1.3B at Jun 30, 2026
  • Phase 3 ACCOMPLISH program for aleniglipron initiated in August 2026; topline data expected in 2H 2028
  • R&D expenses $134.6M in Q3 2026 vs $59.0M in Q3 2025
  • ACCG-2671 MAD trial dosing underway; topline data expected in 1H 2027

Financial Impact

Net loss widened by $79.1M YoY; cash burn of ~$60M in Q3; $1.2B cash runway through 2028

net losscash positionR&D expenses

Risk Factors

  • Cash burn rate is accelerating with Phase 3 costs; $1.2B may not cover pre-commercialization manufacturing costs
  • Aleniglipron Phase 3 data not expected until 2H 2028, leaving a long period without major catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398932

US Market Status

Market Closed · Opens Wed (11h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026